Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | CALCA | P06881 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422080 | 0.95 | KCNH2 (0.50) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52222 | 0.93 | KCNH2 (0.54) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL53197 | 0.92 | CYP2C9 (0.58) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52461 | 0.90 | KCNH2 (0.49) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL63268 | 0.90 | KCNH2 (0.53) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL418769 | 0.89 | KCNH2 (0.48) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52585 | 0.89 | KCNH2 (0.55) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL10143684 | 0.89 | KCNH2 (0.49) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL63480 | 0.89 | KCNH2 (0.48) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 | |
| SCHEMBL52108 | 0.88 | CYP2C9 (0.54) | KCNH2CYP2C9SMN1; SMN2KCNE1CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2280981-B1 | BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-04-23 | — | — | EP | disclosed |
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | VENKATRAMAN SHANKAR (US) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022045-A1 | BRIDGED COMPOUNDS AS HIV INTEGRASE INHIBITORS | CCND3, CDK3, CDK2 | KCNH2 2502/4885CYP2C9 1960/4885SMN1; SMN2 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.